Onur Dalgıç

Dr. Onur Dalgıç

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in The Anatolian Journal of Cardiology
Verified
Journal Article
Open access
VOVeysel Oktay
Veysel Oktay
OTOmaç Tüfekçioğlu
Omaç Tüfekçioğlu
DYDilek Çicek Yılmaz
Dilek Çicek Yılmaz
EOErsel Onrat
Ersel Onrat
DKDilay Karabulut
Dilay Karabulut
HOHüseyin Onay
Hüseyin Onay
Hypertrophic cardiomyopathy is a common genetic heart disease and up to 40%-60% of patients have mutations in cardiac sarcomere protein genes. This genetic diagnosis study aimed to detect pathogenic or likely pathogenic sarcomeric and non-sarcomeric gene mutations and to confirm a final molecular diagnosis in patients diagnosed with hypertrophic cardiomyopathy. A total of 392 patients with hypertrophic cardiomyopathy were included in this nationwide multicenter study conducted at 23 centers across Türkiye. All samples were analyzed with a 17-gene hypertrophic cardiomyopathy panel using next-generation sequencing technology. The gene panel includes ACTC1, DES, FLNC, GLA, LAMP2, MYBPC3, MYH7, MYL2, MYL3, PLN, PRKAG2, PTPN11, TNNC1, TNNI3, TNNT2, TPM1, and TTR genes. The next-generation sequencing panel identified positive genetic variants (variants of unknown significance, likely pathogenic or pathogenic) in 12 genes for 121 of 392 samples, including sarcomeric gene mutations in 30.4% (119/392) of samples tested, galactosidase alpha variants in 0.5% (2/392) of samples and TTR variant in 0.025% (1/392). The likely pathogenic or pathogenic variants identified in 69 (57.0%) of 121 positive samples yielded a confirmed molecular diagnosis. The diagnostic yield was 17.1% (15.8% for hypertrophic cardiomyopathy variants) for hypertrophic cardiomyopathy and hypertrophic cardiomyopathy phenocopies and 0.5% for Fabry disease. Our study showed that the distribution of genetic mutations, the prevalence of Fabry disease, and TTR amyloidosis in the Turkish population diagnosed with hypertrophic cardiomyopathy were similar to the other populations, but the percentage of sarcomeric gene mutations was slightly lower.

17 December 2022 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
UKUmut Kocabaş
Umut Kocabaş
IEIsil Ergin
Isil Ergin
VYVeysel Yavuz
Veysel Yavuz
SMSelda MURAT
Selda MURAT
IÖIbrahim Özdemir
Ibrahim Özdemir
SOSefa Okar
Sefa Okar

19 January 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Open access
PDF file
UKUmut Kocabaş
Umut Kocabaş
IEIsil Ergin
Isil Ergin
VYVeysel Yavuz
Veysel Yavuz
SMSelda MURAT
Selda MURAT
IÖIbrahim Özdemir
Ibrahim Özdemir
OIon behalf of the ANATOLIA-A. F. study investigators
on behalf of the ANATOLIA-A. F. study investigators

27 January 2025 in Clinical Cardiology
Verified
Journal Article
Open access
UKUmut Kocabaş
Umut Kocabaş
IEIsil Ergin
Isil Ergin
SSSadi Can Sönmez
Sadi Can Sönmez
VYVeysel Yavuz
Veysel Yavuz
SMSelda MURAT
Selda MURAT
TKTarik Kivrak
Tarik Kivrak
Objective: The main objective of this study is to determine the incidence and predictors of clinical outcomes in patients with AF treated with factor Xa inhibitors in a real‐world setting.Methods: The present study was a multicentre and observational study that included patients with AF who were treated with factor Xa inhibitors. The primary outcome was the composite of ischemic stroke, TIA, systemic embolism, major bleeding, and all‐cause mortality.Results: A total of 1162 patients from 26 cardiology centers were included in this study, with a median age of 72 years. During the median 12‐month follow‐up period, the primary outcome occurred in 195 patients (16.8%). Treatment with rivaroxaban compared with apixaban and edoxaban showed a lower rate of ischemic stroke, TIA, and/or systemic embolism (2.2% vs. 4.7% vs. 6.5%, respectively, p = 0.014). The major bleeding rate was similar between all three factor Xa inhibitors. The all‐cause mortality rate in the rivaroxaban group was lower compared with the apixaban and edoxaban groups (9.8% vs. 15.1% vs. 12.4%, respectively, p = 0.042). Overall, the frequency of primary outcome was 13.8%, 19.6%, and 20.6% for patients treated with rivaroxaban, apixaban, and edoxaban, respectively (p = 0.019). Older age, male sex, low body weight, high bleeding risk, heart failure, hypertension, liver failure, and treatment with apixaban 2.5 mg b.i.d. were independently associated with the development of primary outcome.Conclusion: The follow‐up data from the ANATOLIA‐AF study provides detailed data about the incidence and independent predictors of adverse clinical outcomes in patients with AF treated with factor Xa inhibitor treatment.

30 August 2019 in Family Practice and Palliative Care
Verified
Journal Article
Open access
PDF file
DADincer Ati̇lA
Dincer Ati̇lA
ODOnur Dalgic
Onur Dalgic
YÖYasemin KILIÇ ÖZTÜRK
Yasemin KILIÇ ÖZTÜRK
Introduction: Atherosclerotic cardiovascular diseases are the leading causes of death worldwide. Both hypertension and obesity are frequent in Turkey and are seen in around 30% of the population. This study aimed to determine the prevalence of hypertension and to investigate its relationship with obesity in patients admitted to a cardiology outpatient clinic. Methods: This descriptive cross-sectional study was conducted between the 15th of January and the 28th of February 2018 at the Medical Park İzmir Hospital Cardiology Polyclinics. Data were collected from 55 out of 256 people who were referred to the clinic on the specified dates. Data were collected about systolic and diastolic blood pressures, height, weight, gender, age category, educational status, marital status, and history of hypertension. Results: Of the participants, 35 (63.6%) were men, and 20 (36.4%) were women. The mean age and body mass index values were 44.60±11.03and 28.18±3.89kg/m2, respectively. In total, 85.4% were overweight or obese. The mean systolic and diastolic blood pressures were 140.09±7.99 mmHg and 90.69±7.07 mmHg, respectively. 31 (56.4%) patients had systolic, 34 (61.8%) had diastolic, and 37 (67.3%) had systolic or diastolic hypertension. Of those with hypertension, 26 (70.2%) were not aware of their condition. In the regression analysis, gender was the only independent factor predicting high blood pressure (p=0.005; odds ratio=6.4). Conclusion: Hypertension and obesity were common among patients in the cardiology outpatient clinics. Family physicians are expected to be competent in managing common health problems and are focused on preventive health practices, and thus, they should take a more active role in the struggle against hypertension and obesity.

1 January 2026 in International Journal of Hypertension
Verified
Journal Article
Open access
PDF file
EAErkan Alpaslan
Erkan Alpaslan
STSedat Taş
Sedat Taş
ÜTÜmmü Taş
Ümmü Taş
MEMehmet Eyüboğlu
Mehmet Eyüboğlu
ODOMER OZKAN DUMAN
OMER OZKAN DUMAN
AÖAhmet Rıdvan Özdemir
Ahmet Rıdvan Özdemir
Background: P‐wave terminal force in lead V1 (PTFV1) is an electrocardiographic marker of atrial electrical abnormality. We investigated whether β 1‐selective beta‐blocker use was associated with PTFV1 in hypertensive patients with echocardiographically confirmed left ventricular hypertrophy (LVH). Methods: This retrospective study included 182 eligible patients with essential hypertension and LVH selected from 1372 screened patients. Patients were classified as β 1‐selective beta‐blocker users ( n = 82) or nonusers ( n = 100). Abnormal PTFV1 was defined as ≥ 0.04 mm s. Multivariable regression and sensitivity analyses were performed. Results: PTFV1 was lower in beta‐blocker users than in nonusers (0.024 [0.015–0.036] vs. 0.030 [0.020–0.048] mm s, p = 0.005). In the primary adjusted model, beta‐blocker use was associated with lower PTFV1 ( B = −0.008, standardized β = −0.202, 95% CI −0.014 to −0.002, p = 0.009), although model explanatory capacity was limited ( R 2 = 0.064; adjusted R 2 = 0.021; overall p = 0.168). In an extended sensitivity analysis additionally adjusting for diabetes, renal function, and concomitant antihypertensive therapies, beta‐blocker group status remained associated with lnPTFV1 (standardized β = 0.294, p < 0.001; R 2 = 0.147; adjusted R 2 = 0.081; overall p = 0.011). Beta‐blocker use was also associated with lower odds of abnormal PTFV1 (OR = 0.43, 95% CI 0.22–0.84, p = 0.013). Conclusion: β 1‐Selective beta‐blocker use was associated with lower PTFV1 and a lower likelihood of abnormal PTFV1. These findings suggest a more favorable atrial electrical profile but should be considered hypothesis‐generating given the retrospective design and modest model explanatory capacity.